Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 21, 2022 (4 years ago)

Betamethasone Dipropionate Ointment USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Betamethasone Dipropionate Ointment USP, 0.05%* (Augmented) (Potency expressed as betamethasone), 15 gram tube, Rx Only, Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310, Distributed by: McKesson Corporation dba Sky Packaging 4971 Southridge Blvd., Suite 101 Memphis, TN 38141, NDC 63739-996-65

Affected NDC 63739-0996-65

Compare with the code on your package — it is the most precise check available.

Drug: Betamethasone

Recalling firm
McKesson Corporation dba McKesson Drug Company
NDC code
63739-996-65
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0850-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Betamethasone recalls

See all
Class II · Moderate risk

Celestone Soluspan

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 0085-4320-01 D-1089-2022
Class II · Moderate risk

Betamethasone Dipropionate Lotion USP

Failed Stability Specifications: lot did not meet specification for the Active Pharmaceutical Ingredient (API) particle test, which was determined through routine stability testing

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 52565-023-29 D-0297-2022

Other recalls by McKesson Corporation dba McKesson Drug Company

All 2022 recalls
Class II · Moderate risk

Gemcitabine Injection

Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

Ongoing Temperature excursion McKesson D-0714-2026
Class I · High risk

Udenyca

Temperature Abuse. 116 cartons with specific serial numbers of Lot 2199821, were stored incorrectly in a controlled room temperature environment instead of the required refrigerated environment.

Ongoing Temperature excursion McKesson NDC 69448-025-63 D-0353-2026
Class II · Moderate risk

Inflectra (infliximab-dyyb)

cGMP Deviations: Product intended for quarantine was inadvertently distributed.

Ongoing cGMP deviation McKesson NDC 0069-0809-01 D-0213-2025